Rodriguez-Calero, Antonio
Gallon, John http://orcid.org/0000-0002-5328-6298
Akhoundova, Dilara
Maletti, Sina
Ferguson, Alison http://orcid.org/0000-0002-6491-996X
Cyrta, Joanna
Amstutz, Ursula
Garofoli, Andrea
Paradiso, Viola
Tomlins, Scott A.
Hewer, Ekkehard http://orcid.org/0000-0002-9128-0364
Genitsch, Vera
Fleischmann, Achim
Vassella, Erik
Rushing, Elisabeth J. http://orcid.org/0000-0001-7616-6320
Grobholz, Rainer http://orcid.org/0000-0002-1901-7967
Fischer, Ingeborg
Jochum, Wolfram
Cathomas, Gieri
Osunkoya, Adeboye O. http://orcid.org/0000-0001-5712-8134
Bubendorf, Lukas http://orcid.org/0000-0001-5970-1803
Moch, Holger http://orcid.org/0000-0002-7986-2839
Thalmann, George
Ng, Charlotte K. Y. http://orcid.org/0000-0002-6100-0026
Gillessen, Silke
Piscuoglio, Salvatore http://orcid.org/0000-0003-2686-2939
Rubin, Mark A. http://orcid.org/0000-0002-8321-9950
Funding for this research was provided by:
Swiss Cancer League Swiss Personalized Health Network grant SOCIBP
Article History
Received: 6 May 2020
Accepted: 12 April 2022
First Online: 3 May 2022
Competing interests
: S.A.T. and M.A.R. are co-authors (and included in the royalty streams) on the patent US7718369B2 issued to the University of Michigan and the Brigham and Women’s Hospital, on ETS gene fusions that have been licensed to Hologic/Gen-Probe Inc., who sublicensed rights to Roche/Ventana Medical Systems, and LynxDX. S.A.T. has served as a consultant for and received honoraria from Janssen, and Astellas/Medivation. S.A.T. has sponsored research agreements with Astellas/Medivation. S.A.T. is a cofounder of, prior consultant for, equity holder in, and employee of Strata Oncology. S.G. plays a consulting or advisory role to Astellas Pharma (Inst), Curevac (Inst), Novartis (Inst), Active Biotech (Inst), Bristol-Myers Squibb (Inst), Ferring (Inst), MaxiVax, Advanced Accelerator Applications, Roche, Janssen (Inst), Innocrin Pharma (Inst), Sanofi, Bayer (Inst), Orion Pharma GmbH, Clovis Oncology (Inst), Menarini Silicon Biosystems (Inst), MSD (Inst). S.G. is a co-author of the patent Method for biomarker (WO 3752009138392 A1). S.G. is an honorary member of Janssen and has also ties to Nektar, ProteoMediX. M.A.R. is on the Scientific Advisory Board of NeoGenomics, inc. C.K.Y.N. serves as a consultant for Repare Therapeutics USA. L.B. has served as an advisor for Janssen, Bayer, and Roche, has received honoraria from Janssen, and has sponsored research agreement with Novartis. The remaining authors declare no competing interests.